Boise, Idaho - The most significant impact of information therapy on a dermatology practice will be extending the doctor's office into the patient's home, said Donald W. Kemper, chief executive officer of Healthwise, Inc., a healthcare decision-making company. Several years ago Kemper coined "information therapy," or "Ix." The term refers to the provision of current, evidence-based information to patients and their caregivers at each step of diagnosis and treatment.
The FDA approved therapies for melanoma, dermatomyositis, superficial basal cell carcinoma, and adolescent alopecia areata, while TYK2 inhibitors and rare disease filings advanced toward 2027 decisions.
Can at-home dermarollers give the same results as in-office microneedling or is that just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.
The FDA approval, based on 36-week data from the phase 3 BRAVE-AA-PEDS trial, extends baricitinib access to patients as young as 12 years old with severe alopecia areata.